Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2011

View Archived Issues

Final data disclosed from phase II NKTR-102 trial in metastatic breast cancer

Spanish university identifies new biomarker of brain abnormalities in schizophrenia

HPI-1-encapsulating polymeric nanoparticle tested in preclinical models of HCC

Pfizer reports pivotal data on tofacitinib in rheumatoid arthritis

New modified ADAM-derived polypeptides disclosed by USC

Researchers optimize Mer inhibitors for treatment of acute lymphoblastic leukemia

Preclinical and phase I data presented on insulin sensitizer LIM-0705

Several trials assess Anacor's boron-based therapies in healthy subjects and psoriasis

Scientists at BMS prepare novel agents for hepatitis C

New bradykinin B1 receptor antagonists synthesized

Researchers at Merck & Co. disclose new AMPK activators

Novel PLK1 inhibitors claimed by Boehringer Ingelheim Pharma

Ironwood Pharmaceuticals patents new GC-C agonists

Transcept Pharmaceuticals plans next resubmission of Intermezzo NDA

BioAlliance reports preliminary phase I data on AMEP biotherapy

Single-dose NeoVisc approved for sale in Europe

Daiichi Sankyo and AstraZeneca launch Nexium capsules in Japan

Mitsubishi Tanabe and Janssen to market Simponi in Japan

Cempra Pharmaceuticals reports data from phase II solithromycin trial

FDA grants new orphan drug status to Revimmune

FDA grants two fast track designations to QLT's oral synthetic retinoid

Soligenix reports on recent data safety monitoring board review of orBec study

Japanese MHLW grants additional approval to CellCept

Thallion reports on phase II SHIGATEC trial

Takeda advances TAK-438 into phase III trials in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...